Novonix Announces Issuance of 34,824 Shares Following Employee Performance Rights Vesting

Performance Rights Converted to Ordinary Shares in July 2026

On 2 July 2026, Novonix lodged an Appendix 2A with ASX seeking quotation for 34,824 new ordinary shares (ASX:NVX), which were issued the following day. These shares rank equally with existing NVX shares from the issue date. The issuance follows the vesting and conversion of performance rights classified under the NVXAD code as part of the company’s employee incentive scheme.

The company reported that 54,480 NVXAD performance rights were converted on 2 July 2026. The 34,824 shares applied for quotation represent the resulting ordinary shares. Novonix did not provide details on the conversion ratio or specific performance conditions met, only confirming the shares arose from vested performance rights under its employee incentive plan.

Employee Incentive Scheme Results in Non-Cash Share Issuance Valued at $0.155 Each

The shares were issued without cash consideration, described as "ordinary shares issued upon vesting of performance rights," consistent with typical long-term incentive plans used by ASX-listed companies to retain and reward staff. The company disclosed an estimated value of $0.155 per share in the Appendix 2A filing.

This non-cash issuance means no immediate capital inflow to Novonix. Such performance rights plans are common in the resources and technology sectors, aligning employee rewards with shareholder value creation. The converted rights were issued under an employee incentive scheme and were intended to be quoted by ASX at the time of lodgement but were not yet quoted.

Key Management Personnel Participation in Converted Performance Rights

The filing confirmed that key management personnel (KMP) or their associates hold some of the options or convertible securities converted in this event, as required by ASX Listing Rules disclosures. However, the company did not specify which KMP were involved, the proportion of the 54,480 performance rights they held, or the exact performance hurdles met to trigger vesting. Further details on KMP equity holdings are typically found in the company’s annual remuneration report included in its Annual Report to shareholders.

Total Ordinary Shares Reach 991,596,744 After Quotation

Following this issuance, Novonix’s total quoted ordinary shares stand at 991,596,744, as stated in the Appendix 2A. This figure represents the company’s issued capital in the NVX ordinary share class after the transaction. The company noted that this number is automatically generated and may not reflect the current issued capital if other filings are processed simultaneously.

The 34,824 shares represent less than 0.004% of the total shares outstanding, resulting in minimal dilution to existing shareholders. However, ongoing conversions of performance rights and other convertible instruments may incrementally increase the share count over time.

Remaining NVXAD Performance Rights Total 21,565,395

After this conversion, 21,565,395 NVXAD performance rights remain unquoted and unvested. These rights could lead to further share issuances if performance conditions are met. The company did not disclose the vesting schedule, expiry dates, or specific hurdles for these remaining rights.

This NVXAD pool is the largest unquoted equity class by number of securities, exceeding the 14,016,667 NVXAA options and 1,371,566 NVXAM share rights. Full conversion of all remaining NVXAD rights would represent a more significant increase in shares than the current transaction, though timing depends on performance conditions attached to each tranche.

Convertible Notes and Debentures Remain Key Unquoted Securities

Novonix’s capital structure also includes two classes of debt-linked convertible securities: 45,221,586 NVXAL convertible notes and 35,000,000 NVXAH convertible debentures, both unquoted. These instruments could convert into ordinary shares in the future under their terms.

The filing did not provide details on conversion prices, maturity dates, or interest rates for these convertible notes and debentures. Such information is typically disclosed in original issue terms or periodic reports. Investors assessing potential dilution from these instruments should review those disclosures, as their conversion would add substantially more shares than performance rights conversions.

Performance Rights Vesting Integral to Novonix’s Long-Term Incentive Strategy

Novonix, headquartered in Brisbane and specializing in high-performance anode materials for lithium-ion batteries, employs a long-term incentive plan as part of its employee remuneration framework. Performance rights plans are common among ASX-listed companies in battery materials and clean energy sectors to attract and retain specialized talent. Vesting events, such as this one, deliver equity rewards to eligible employees upon achieving defined criteria.

The company did not comment on the specific financial or operational targets met for the NVXAD rights vested in this cycle. Within Novonix’s broader business activities—including synthetic graphite anode production and technology licensing—such incentive plan operations are standard governance matters rather than strategic announcements. Each vesting event is reported to ASX to maintain transparency on changes to share capital and ownership.

Additional Equity Incentives Include Share Rights and Options

Besides NVXAD performance rights, Novonix’s unquoted securities include 1,371,566 NVXAM share rights and 14,016,667 NVXAA options with various expiry dates and exercise prices. These multiple classes of equity incentives reflect a layered long-term employee remuneration approach developed over several years.

The NVXAA options represent a further potential source of ordinary shares if exercised before expiry, provided exercise prices are favorable. The company did not disclose specific exercise prices or expiry dates for these options in this filing. Interested investors should consult prior issuance notices and annual reports for full details on these instruments.

Market Impact and Investor Focus on Novonix’s Capital Developments

The immediate share price effect of this small-scale issuance was not evident from public information. Given the minimal number of shares relative to nearly one billion total shares, such routine performance rights conversions typically do not impact market prices. Investors are more likely to focus on Novonix’s operational progress, offtake agreements, and commercialisation milestones in battery materials as key share price drivers.

Looking forward, investors should watch for further vesting events from the remaining NVXAD performance rights, updates on NVXAL convertible notes and NVXAH debentures, and any new grants under the employee incentive scheme. The total share count is approaching one billion, and future vesting or conversions may push it beyond that milestone. Regular monitoring of Appendix 2A filings offers insight into the pace of equity dilution from incentive arrangements.